Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients

Addictive Behaviors

Volumn 38, Issue 3, 2013, Pages 1669-1671

  Marini, Valeria ^a   Fucile, Carmen ^a   Zuccoli, Maria Laura ^a   Testino, Giovanni ^b   Sumberaz, Alessandro ^b   Robbiano, Luigi ^a   Martelli, Antonietta ^a   Mattioli, Francesca ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alcoholism; Detoxification from alcohol dependence; OPRM1; Polymorphism

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; MU OPIATE RECEPTOR;

ADULT; ALCOHOLISM; ALLELE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; DRINKING BEHAVIOR; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; TREATMENT DURATION;

ALCOHOLISM; CASE-CONTROL STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 84871066714     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2012.09.015     Document Type: Article

References (12)

1. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9608-9613.
2. Conigrave K.M., Davies P., Haber P., Whitfield J.B. Traditional markers of excessive alcohol use. Addiction 2003, 98:31-43.
3. Franke P., Wang T., Möthen M.M., Knapp M., Neith H., Lichtermann D., et al. Susceptibility for alcoholism: DRD4 exon III polymorphism: a case-control and a family-based association approach. Addiction Biology 2000, 5:289-295.
4. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Current Topics in Medicinal Chemistry 2004, 4:39-50.
5. Lichtermann D., Franke P., Maiser W., Rao M. Pharmacogenomics and addiction to opiates. European Journal of Pharmacology 2000, 410:269-279.
6. Mague S.D., Blendy J.A. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug and Alcohol Dependence 2010, 108:172-182.
7. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsycopharmacology 2003, 28:1546-1552.
8. Ray L.A., Hutchison K.E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism, Clinical and Experimental Research 2004, 28:1789-1795.
9. Sillanaukee P. Laboratory markers of alcohol abuse. Alcohol and Alcoholism 1996, 31:613-616.
10. Stromberg M.F., Rukstalis M.R., Mackler S.A., Volpicelli J.R., O'Brien C.P. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacology, Biochemistry, and Behavior 2002, 72:483-490.
11. Wood P.L. Multiple opiate receptors: support for unique mu, delta and Kappa sites. Neuropharmacology 1982, 21:487-497.
12. Zhang Y., Wang D., Johnson A.D., Papp A.C., Sadée W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. The Journal of Biological Chemistry 2005, 280:32618-32624.